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People with severe mental illness are at higher risk for HIV
infection than the general population. Early studies in
New York1 suggested that the prevalence of HIV infection
among people with severe mental illness was variable,
depending on factors such as homelessness, treatment
setting and status, speciﬁc psychotic diagnosis, dual
diagnosis with substance use disorders, and sampling
method (open vs anonymous). General population risk
factors for HIV infection also have their expected eﬀects
in people with severe mental illness, including high-risk
sexual activity (among men who have sex with men,
heterosexuals, or injection drug users), injection drug use,
ethnicity, gender, age, and viral load at time of exposure.
Additional factors directly related to severe mental illness
are cognitive impairment and psychotic symptoms that
impede the planned use of precautions for risk in sexual
activity and injection drug use, which present special
diﬃculties to controlling HIV in this population.2 Thus,
the eﬃcacy of antipsychotic treatment and adherence to
treatment is relevant to the risk of blood-borne infections
in people with severe mental illness.
In The Lancet Psychiatry, Elisabeth Hughes and
colleagues3 make a major contribution to this subject by
examining the prevalences of HIV, hepatitis C virus, and
hepatitis B virus infection simultaneously in patients
with severe mental illness. They used a well-deﬁned
approach to identify relevant articles and to deﬁne
the studies by speciﬁc conditions of testing (although
“AIDS” could have been added as a search term and
AIDSLine as a database). They included people aged
older than 15 years, diagnosed with severe mental
illness, and treated in a psychiatric setting. Studies in
which prevalence data were obtained only from case
notes, self-report, or the grey literature were excluded.
They determined the eligibility of studies by a consensus
strategy and used the Quality Assessment Tool for
Systematic Reviews of Observational Studies4 to assess
study quality. Hughes and colleagues3 modiﬁed the tool
to show whether participants were clearly deﬁned as
having severe mental illness (yes or no), participation
rate (>60%=1, ≤60%=0), whether control variables
were used (controlled=1, only descriptive=0), and
sample size (≥200 participants=1, <200 participants=0),

although the eﬀects of these modiﬁcations on reliability
and validity are not known. They did a meta-analysis
to calculate combined estimates and 95% CIs for each
continent. Logistic regression was done to allow for
the proportions being unable to have values less than
0, and random eﬀects were assumed because there was
clear clinical heterogeneity among the samples.
The 373 reports they found included 169 (45%)
duplicates and they excluded 41 (11%) because the
full-text was not available in English and 74 (20%)
because they were deemed ineligible. With the addition
of two papers from an updated search, the authors
had 91 articles for assessment. This reduction might
limit the generalisability of the ﬁndings. HIV infection
had the largest sample size and was the subject of the
most studies: 44 studies assessed HIV (21 071 patients),
19 assessed hepatitis B virus (8163 patients), and
28 studies assessed hepatitis C virus (14 888 patients).
Most of the HIV and hepatitis C virus studies were
from the USA, and few were from Europe, although
the investigators attempted to control for continent.
Ultimately, the most important unit for analysis here
might be number of studies rather than the cumulative
number of participants across studies.5
Most studies used convenience samples from
in-patient psychiatric treatment settings; yet, the
studies show that data from patients who are not in
treatment are needed to best approximate the entire
population of patients with severe mental illness.1 It is
also important to estimate the number of patients with
severe mental illness who are dually diagnosed with
substance use disorders to maximise generalisability,
because blood-borne infections are much more common
in this group.6 Another issue not addressed by Hughes
and colleagues3 was the percentage of patients with
dual and triple co-infections. Hepatitis C virus coinfection occurs in as many as 25% of patients with HIV
in the USA.7 Worldwide, 10% of patients with HIV are coinfected with hepatitis B virus,8 with as many as 20% in
southeast Asia. The exact number of patients co-infected
with hepatitis B virus and hepatitis C virus is unknown;
an estimated 9–30% of patients with chronic hepatitis
B virus infection are co-infected with hepatitis C virus.9
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Finally, triple infection has been reported in less than 1%
of residents in Nairobi, Kenya,10 and in as many as 12%
of patients with HIV infection in central China.11 Hence,
assessing the proportion of patients with severe mental
illness who have these co-infections would be of interest.
For patients with HIV, a report of their CD4 cell count
and Centers for Disease Control and Prevention clinical
disease stage at the time of infection would be useful
to gauge the chronicity of infection and relate it to the
psychiatric and trauma history of these patients. The
distribution of HIV risk factors in this subgroup would
also be worthy of examination.
Hughes and colleagues3 state that although 30–50% of
patients with severe mental illness have substance use
disorders, intravenous drug use in this population is rare.
Yet, the primary route of transmission of hepatitis B virus
and hepatitis C virus is by intravenous drug use (globally
roughly 90% for hepatitis C virus), and intravenous drug
use is a lesser but signiﬁcant risk for HIV infection. More
than 25% of homeless people with severe mental illness
in one study reported the use of intravenous drugs at
some time in their lives,12 which is probably generally
representative of the USA. Another factor that bears
on estimates of the prevalence of these viral infections
in people with severe mental illness is the percentage
of homeless patients included in these studies.
Although all the studies included patients characterised
as having severe mental illness, the proportions of
speciﬁc psychotic diagnoses in each sample varied,
and the method of ensuring that patients had severe
mental illness rather than simply being psychiatric inpatients was not presented. Furthermore, although the
sensitivity analyses showed no eﬀect of study quality
on these prevalences, the lack of such an eﬀect does not
prove that study quality is irrelevant.
In conclusion, Hughes and colleagues’ focus on the
concomitant estimations of prevalence of HIV, hepatitis
B virus, and hepatitis C virus infections in people
with severe mental illness is an important ﬁrst eﬀort
to examine the broader issue of this group’s medical
susceptibility. Future studies should examine the
prevalence of co-infections of these three viruses, the
relations between risk factors and contracting infection
as well as the necessary controls needed in analyses
for each of these infections. The generalisability of the
risk factor distributions reported should be assessed
separately against those of the entire population
www.thelancet.com/psychiatry Vol 3 January 2016

for each infection. A random sampling approach
would be helpful in future studies of this population.
Most importantly, it cannot be concluded that only
typical viral risk factors apply to this population
when the risk factors speciﬁc to patients with severe
mental illness have not been taken into account
(eg, cognitive impairment and psychotic symptom
severity). Patients with severe mental illness often
have chronic cognitive impairment, which can impede
their adherence to antipsychotic medications, resulting
in ongoing psychotic symptoms that prevent access
to and implementation of precautions to prevent
these infections. Future research should assess the
contributions of these factors to the additional risk for
these infections in patients with severe mental illness.
Health providers in the USA should discuss sexual
health and risk for blood-borne viral infections with
patients who have severe mental illness and oﬀer HIV
testing to all patients aged 13–64 years at least once
in their lifetime and oﬀer hepatitis C virus testing once
to all adults born between 1945 and 1965 (without
previous ascertainment of risk factors for hepatitis
C virus), as per guidelines of the Centers for Disease
Control and Prevention; screening for hepatitis B virus
should be oﬀered only under speciﬁc circumstances
(continuing risk should result in more frequent testing).
Internationally, WHO sets screening guidelines for HIV,
hepatitis B virus, and hepatitis C virus.
Karl Goodkin
Department of Psychiatry and Behavioral Sciences, Quillen College
of Medicine, East Tennessee State University, PO BOX 70567,
TN 37614, USA
goodkin@etsu.edu
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Over the past decade the personal, family, societal,
and global negative eﬀects of depression have been
unequivocally demonstrated.1 Untreated depression
is a major public health issue that aﬀects both mental
and physical health and many aspects of personal and
public life, including relationships and educational
outcomes.
Despite the growing evidence base
highlighting the need to reach populations at increased
risk of developing depression and the importance of
intervening in the adolescent period,2–4 primary care and
mental health services have remained poorly resourced
and, therefore, predominantly reactive. The group most
likely to receive treatment for depression are those
able to seek services and engage with the treatment
approaches on oﬀer. Some subgroups are poorly
represented, such as children,5 who are dependent on
adults to identify their needs, advocate for them, and
enable them to access services. In most high-income
countries, less than half of the children who need
mental health services are actually seen;5 these ﬁgures
are considerably worse for low-income and middleincome settings.6 It is therefore essential to address
why the majority of children do not access services in a
timely or consistent manner.2
In The Lancet Psychiatry, Stephan Collishaw and
colleagues7 present ﬁndings from a community sample
of parents with recurrent depressive episodes studied
over 4 years. They report on a small subsample of
oﬀspring who were more resilient than the others—only
53 (20%) of 262 study children (mostly adolescents)
did not experience concerning psychological symptoms
or had better than expected outcomes. They explore
the possible explanations for these better outcomes
and highlight some protective factors. The factors that
bestow greatest protection include the presence of
supportive co-parents, good quality social relationships,
self-eﬃcacy, and regular exercise.

This study highlights the combined role protective
factors might have for adolescents at risk of depression
as the oﬀspring did better with increasing protective
factors present. Further studies will hopefully
conduct more detailed multidisciplinary enquiry of
a greater range of protective factors investigating
several domains (such as those within families, peer
groups, schools, communities, and beyond). Multiple
perspectives, including the voice of the young person,
can only improve our understanding of the many
potential inﬂuences at play. Focusing on protective
factors adds an important dimension to preventive
interventions. These ﬁndings, alongside other key
studies, reinforce the importance of thinking about
family-approaches to identifying and treating
depression. For example, the data from STAR*D8
highlighted how the treatment of maternal depression
signiﬁcantly improves the mental health outcomes of
school-aged oﬀspring. Patton and colleagues4 showed
the importance of early identiﬁcation and treatment
for adolescent depression, as good outcomes are more
likely if the ﬁrst episode of adolescent depression is
identiﬁed early and treated.
Two important messages need to be emphasised.
First, for those treating adults with a depressive
disorder, an appreciation of the risk to any oﬀspring
must be acknowledged and addressed. In the study
reported here,7 most children with depressed parents
had symptoms of concern. The majority of depression
is managed in primary care settings, but a proportion
are managed in secondary care and yet family-based
approaches supporting carers and oﬀspring are poorly
studied and rarely available. The treating clinician
might experience philosophical and practical barriers
to identifying and including the highest risk family
members within their treatment plan, yet some
examples of family-focused care and family-friendly
www.thelancet.com/psychiatry Vol 3 January 2016

